Research programme: otitis media therapeutics - OticPharma

Drug Profile

Research programme: otitis media therapeutics - OticPharma

Alternative Names: OP 0201; OP-02; OP-02 Surfactant

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator otodyne
  • Developer Otic Pharma; Otodyne
  • Class Palmitates; Phospholipids; Surfactants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Otitis media

Most Recent Events

  • 30 Dec 2016 Preclinical trials in Otitis media in USA (unspecified route) (Otic Pharma pipeline, December 2016)
  • 22 Dec 2016 Otic Pharma plans a phase II trial for Otitis media (In children) in USA
  • 22 Dec 2016 Otic Pharma plans a phase I trial for Otitis media in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top